RPG Life Sciences (RPGLIFE) Investor Presentation summary

Business overview and market presence

• Integrated pharmaceutical company with operations in branded formulations, global generics, and synthetic APIs for both domestic and international markets.

• Domestic formulations account for 67% of business, international formulations 18%, and APIs 15%.

• Presence in over 50 markets and leadership in immunosuppressants with 9 high-equity brands.

• Operates 3 manufacturing facilities and employs over 1,200 people.

Financial performance and growth

• FY24 sales grew by 14%, EBITDA by 26%, and margins expanded by 229 bps.

• ROCE reached 31.0%, ROE 23.4%, and EPS Rs. 53.0.

• New products contributed ~30% to sales, with 13% volume growth and 118% increase in market capitalization.

• Profit margins and key financial ratios have shown consistent year-on-year improvement.

• Market capitalization increased 9x from Mar 2020 to Mar 2024.

Strategic initiatives and operational excellence

• Comprehensive life cycle management of legacy products and new product launches across segments.

• Expansion into new therapies and multiple initiatives to grow prescriber and patient base.

• Revenue and cost optimization projects, digitalization, and innovation drive performance.

• Capex of ~INR 140 crores to modernize plants and R&D infrastructure.

• Recognized for best patent, CSR, brand, company, and values; high employee happiness score.